Propulsid Limited Access Program Allows Off-Label Use To Continue
Executive Summary
FDA and Johnson & Johnson are indicating that the new Propulsid limited access program will allow physicians to continue prescribing the drug for more serious conditions than nocturnal heartburn due to gastroesophageal reflux disease, the labeled indication.
You may also be interested in...
FDA Seeks Alternatives To QT Interval For Assessing Risk Of Torsade de Pointes
A clinical study funded by the Critical Path Initiative is looking at the change in a number of electrocardiogram parameters in patients given drugs known to prolong the QT interval and with varying risks for the abnormal heart rhythm.
J&J Propulsid Compassionate IND Program Expands To Allow Emergency Use
Janssen is adding three IND treatment protocols to its limited access program for Propulsid (cisapride).
J&J Propulsid Compassionate IND Program Expands To Allow Emergency Use
Janssen is adding three IND treatment protocols to its limited access program for Propulsid (cisapride).